Zobrazeno 1 - 10
of 44
pro vyhledávání: '"L J, Denis"'
Autor:
E.F. Smit, Mehdi Shahidi, William Pao, Yelena Y. Janjigian, Vincent A. Miller, L. J. Denis, Harry J.M. Groen, Yali Fu, F. Wang, Leora Horn
Publikováno v:
Journal of Clinical Oncology, 29(15 Supplement):7525. AMER SOC CLINICAL ONCOLOGY
7525^ Background: Despite initial responses to reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, (erlotinib or gefitinib), all non-small cell lung cancer (NSCLC) patients with EGFR-sensitizing mutations experience disease
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03c368b12d6d8211367213413997a526
https://doi.org/10.1200/jco.2011.29.15_suppl.7525
https://doi.org/10.1200/jco.2011.29.15_suppl.7525
Autor:
F H, Schröder, L J, Denis, M, Roobol, V, Nelen, A, Auvinen, T, Tammela, A, Villers, X, Rebillard, S, Ciatto, M, Zappa, A, Berenguer, A, Paez, J, Hugosson, P, Lodding, F, Recker, M, Kwiatkowski, W J, Kirkels
Publikováno v:
BJU international. 92
disease. In this respect the publication by Catalona et al. [4] and preceding oral presentations gave crucial details. At the same time it became clear that case-finding studies conducted around the world would be unable to produce evidence that scre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b128573b81f1f33dfd9d28a9a667b14
https://pubmed.ncbi.nlm.nih.gov/14983946
https://pubmed.ncbi.nlm.nih.gov/14983946
Autor:
N C, Levitt, F A, Eskens, K J, O'Byrne, D J, Propper, L J, Denis, S J, Owen, L, Choi, J A, Foekens, S, Wilner, J M, Wood, M, Nakajima, D C, Talbot, W P, Steward, A L, Harris, J, Verweij
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 7(7)
This Phase I study of MMI270, an p.o. administered matrix metalloproteinase inhibitor, assessed toxicity, pharmacokinetics, and tumor response data and investigated markers of biological activity to recommend a dose for Phase II studies. MMI270 was a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b2d231d37f86b6c78040c69fd3879699
https://pubmed.ncbi.nlm.nih.gov/11448904
https://pubmed.ncbi.nlm.nih.gov/11448904
Publikováno v:
The Prostate. 48(1)
The meta-analysis of maximal androgen blockade (MAB) concluded that there is no survival advantage of MAB over castration alone. However, the results from the largest trials yield conflicting results.The design and results of three trials were examin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6698a0e5ca9aa3e3d7ba78b667ed22e6
https://pubmed.ncbi.nlm.nih.gov/11391684
https://pubmed.ncbi.nlm.nih.gov/11391684
Autor:
K, Griffiths, L J, Denis
Publikováno v:
The Prostate. Supplement. 10
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c01f9a306e382d99c795deda8a4cf005
https://pubmed.ncbi.nlm.nih.gov/11056493
https://pubmed.ncbi.nlm.nih.gov/11056493
Autor:
C D, Britten, S D, Baker, L J, Denis, T, Johnson, R, Drengler, L L, Siu, K, Duchin, J, Kuhn, E K, Rowinsky
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 6(9)
Oral paclitaxel is not inherently bioavailable because of the overexpression of P-glycoprotein by intestinal cells and the significant first-pass extraction by cytochrome P450-dependent processes. This study sought to simulate the toxicological and p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6d602bf1333095e5acdaf81b40752cf1
https://pubmed.ncbi.nlm.nih.gov/10999729
https://pubmed.ncbi.nlm.nih.gov/10999729
Autor:
F A, Eskens, G A, Greim, C, van Zuylen, I, Wolff, L J, Denis, A S, Planting, F A, Muskiet, J, Wanders, N C, Barbet, L, Choi, R, Capdeville, J, Verweij, A R, Hanauske, U, Bruntsch
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 6(5)
A single-agent dose-escalating Phase I and pharmacological study of the polyamine synthesis inhibitor SAM 486A was performed. A dosing regimen of four weekly infusions followed by 2 weeks off therapy was studied. Fifty patients were entered into the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3566f7b038c716d7babf39b1264308f4
https://pubmed.ncbi.nlm.nih.gov/10815892
https://pubmed.ncbi.nlm.nih.gov/10815892
Autor:
L J, Denis, K, Griffiths
Publikováno v:
Seminars in surgical oncology. 18(1)
Over its natural course, prostate cancer is a heterogeneous tumour with a generally slow but constant rate of growth. The androgen dependence of the prostate gland was demonstrated more than half a century ago by the landmark studies of Professor C.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::091717bdd235fbb366e9dc1752b5c451
https://pubmed.ncbi.nlm.nih.gov/10617897
https://pubmed.ncbi.nlm.nih.gov/10617897
Autor:
R, Kirby, C, Robertson, A, Turkes, K, Griffiths, L J, Denis, P, Boyle, J, Altwein, F, Schröder
Publikováno v:
The Prostate. 40(2)
It was very reasonable to consider that the combination of the 5alpha-reductase, finasteride, and a pure antiandrogen such as flutamide should provide an effective form of maximal androgen blockade (MAB). Finasteride decreases intraprostatic levels o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8ab10e84ba7cf8450ca51fce1a0ca555
https://pubmed.ncbi.nlm.nih.gov/10386471
https://pubmed.ncbi.nlm.nih.gov/10386471
Publikováno v:
The Prostate. 38(2)
The first data analysis of the European Organization for Research and Treatment of Cancer (EORTC) 30853 trial indicated a significantly longer time to progression and duration of survival for the maximal androgen blockade (MAB) treatment arm. However
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::62bf9fbba4ba9c3a85a6f6bb2e7b38f6
https://pubmed.ncbi.nlm.nih.gov/9973095
https://pubmed.ncbi.nlm.nih.gov/9973095